Business Wire

Altasciences Conducts Successful First-in-human Trial for Acurx Pharmaceuticals’ Novel Antibiotic to Treat C. Difficile Infection

Share

On behalf of the sponsor, Acurx Pharmaceuticals, Altasciences is proud to have successfully completed the clinical conduct, data management, and SAS programming for ACX-362E, a novel, oral antibacterial agent for the treatment of Clostridioides difficile infection (CDI), an acute, serious, potentially life-threatening, intestinal infection. Altasciences efficiently recruited and retained 62 healthy normal subjects for this first-in-human, randomized, double-blind, placebo-controlled, multiple-ascending dose trial, single and multiple ascending dose phase I study to determine the safety, pharmacokinetics, food, and fecal microbiome effects of ACX-362E administered orally to healthy subjects which had a secondary objective to determine the fecal microbiome effects of ACX-362E compared to those of oral vancomycin.

Dr. Kevin Garey, Professor and Chair, University of Houston College of Pharmacy and the Principal Investigator for the microbiome aspects of the trial presented the study results at last week’s IDWeek™ Scientific Conference as a “Late-Breaker presentation.” Dr. Garey concluded: "The safety data from the Phase 1 trial are impressive with fecal concentrations comparable to those observed with precedent products that have advanced to demonstrate clinical success. Most notable is the ground-breaking comparison of the effects of ACX-362E versus the standard of care on the normal human gut microbiome. Microbiome analysis demonstrated that ACX-362E has a significantly more favorable effect than oral vancomycin due to less disruption of the microbiota in the gastrointestinal tract. This differential was especially pronounced among the phyla, Bacteroidetes and Firmicutes which generally comprise up to 90% of the healthy human gut microbiome."

The trial, conducted at Altasciences’ clinical pharmacology unit in the U.S.A., provided the first evidence of human safety in single and multiple-ascending doses and a favorable PK profile. Fecal concentrations exceeded those known to inhibit C. difficile several hundred-fold, and blood levels showed low systemic exposure, indicating poor oral absorption as desired to treat CDI.

Angela Phillips, Altasciences’ Senior Director of Clinical Operations said: “We are pleased to have partnered with Acurx Pharmaceuticals to advance a new treatment for this serious, potentially life-threatening, intestinal infection that could change the lives of affected patients. Altasciences’ decades of experience in study participant recruitment and first-in-human trials helped deliver timely results that support the development of effective treatments, such as ACX-362E.”

About Altasciences

Altasciences is a forward-thinking, mid-size contract research organization offering pharmaceutical and biotechnology companies of all sizes a proven, flexible approach to preclinical and early phase clinical studies, from lead candidate selection to proof of concept. For over 25 years, Altasciences has been integrating into clients’ projects to help support educated, faster, and more complete early drug development decisions. Altasciences’ full-service solutions include preclinical safety testing, clinical pharmacology, bioanalysis, program management, medical writing, biostatistics, and data management, all of which can be tailored to specific sponsor requirements. Altasciences… helping sponsors get better drugs to the people who need them, faster.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Julie-Ann Cabana
Altasciences

913 304-4505
jcabana@altasciences.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Aizon Launches New AI-powered eBR Light Solution to Enhance Manufacturing Productivity in Collaboration with Euroapi18.9.2024 19:00:00 EEST | Press release

Aizon, an Artificial Intelligence (AI) SaaS provider dedicated to transforming pharmaceutical manufacturing operations, is launching a new product called Aizon Execute, an innovative eBR (Electronic Batch Record) software product, developed in collaboration with Euroapi, a leading global API manufacturer. This collaboration was born out of the need to digitize operations towards more data-driven manufacturing - focusing on the essential user needs while avoiding the heavy lift currently associated with going paperless in manufacturing. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240918037613/en/ Aizon Execute is a modern, user-centric, lightweight product designed to adapt to small-scale productions and highly flexible plants like chemical API CDMOs - and has the potential to become the true backbone of digital transformation journeys. Aizon Execute light eBR is designed to facilitate the rapid transition from paper-based

Headline Closes $865 Million to Invest in Growth-Stage Tech Companies18.9.2024 18:53:00 EEST | Press release

Headline today announced Headline Global Growth IV with $865M1 of capital committed to the strategy to support companies at their Growth inflection points, Series B and beyond. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240918812241/en/ Headline's Global Growth Equity Team (Photo: Business Wire) The Global Growth strategy has three distinct advantages: a diverse and experienced team, extensive geographic coverage, and advanced in-house built technology for sourcing (Searchlight) and analytics (DeepDive). Led by seasoned Growth investor Shalini Rao, the Growth team is committed to identifying and nurturing "Paradiesvögel"—tenacious technology founders poised for global success. Recent team additions to Headline Global Growth include Nancy Xiao, Trevor Neff, Reda Bensaid, Jake Horwitz and Austin Hack, all of whom will work out of Headline’s San Francisco and European offices. Global Growth IV represents the evolution of gr

New Garmin G5000 Avionics Upgrade Now Available for Cessna Citation XLS Aircraft at Textron Aviation Service Centers18.9.2024 18:00:00 EEST | Press release

Textron Aviation today announced customers can now upgrade their Cessna Citation XLS+ and Citation XLS Gen2 aircraft with the Garmin G5000 integrated flight deck following Garmin’s receipt of FAA supplemental type certification (STC) for the avionics upgrade. Customers can have the upgrade installed at selected domestic Textron Aviation Service Centers to add significant technological advances and new capabilities to their aircraft. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240918046690/en/ New Garmin G5000 avionics upgrade now available for Cessna Citation XLS aircraft at Textron Aviation Service Centers. (Photo: Garmin, Textron Aviation) Beechcraft, Cessna and Hawker customers receive factory-direct support, maintenance and modifications by Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, through a global network of service and part centers, mobile service units and 24/7 1CALL AOG support. “The G5000 avionic

ProAmpac Brings Fiberization and Sustainable Packaging Innovation to FACHPACK 202418.9.2024 17:45:00 EEST | Press release

ProAmpac, a leader in flexible packaging and material science, will showcase its latest sustainable packaging solutions at FACHPACK 2024 from September 24-26 in Nuremberg, Germany. At stand 5-126, ProAmpac will present advanced offerings such as ProActive Recyclable® FibreSculpt, ProActive Intelligence® Moisture Protect MP-1000, and the ProActive Recyclable® RP-1050, alongside its RAP Packaging line of fiber-based food-to-go solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240918028305/en/ FibreSculpt (Photo: Business Wire) “We invite attendees to explore ProAmpac’s innovative solutions driving the fiberization of packaging,” said Alex Baumgartner, president of ProAmpac’s European division. “From our MP-1000 technology, which transforms moisture control in powdered beverages and nutraceuticals, to our fiber-based food-to-go packaging, these advancements meet the growing demand for sustainable, high-performance packa

Takeda Commits Over $32 Million in Five New Global Corporate Social Responsibility Partnerships to Further Drive Health Impact in 93 Countries18.9.2024 17:00:00 EEST | Press release

Takeda (TOKYO:4502/NYSE: TAK) today committed JPY4.6 billion (Approx. USD 32 million) to five new Global Corporate Social Responsibility (CSR) partners as part of the company’s ongoing commitment to improving health systems resiliency in low and middle-income countries around the world. This commitment demonstrates Takeda’s focus on tackling systemic disparities and supporting local leadership in strengthening health infrastructure, empowering health workforce, and increasing local knowledge and capacity to improve equitable and sustainable healthcare access and delivery. By 2030, these new collaborations are anticipated to extend Takeda’s impact to 27 million people across 93 countries, raising the total contributions from Takeda’s Global CSR Program to over JPY 28.8 billion (Approx. USD 199.1 million) across 34 significant partnerships since it began in 2016. The five new partners were selected by more than 22,000 Takeda employees across 80 countries and regions through a company-wid

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye